CSPC's KN026 meets primary endpoint in gastric cancer study
CSPC Pharmaceutical Group Limited (HKEX:1093) announced that its pivotal Phase II/III clinical study (KC-WISE) of KN026, a HER2 bispecific antibody injection co-developed with Shanghai JMT-Bio and Jiangsu Alphamab Oncology, met its primary endpoint of progression-free survival (PFS) at an interim analysis. The study focuses on treating patients with HER2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma who have failed at least one prior systemic treatment. The Independent Data Monitoring Committee (IDMC) confirmed statistical significance and clinical relevance of the results. KN026 had previously been granted Breakthrough Therapy Designation by China's CDE in November 2023. The KC-WISE study is randomized and multicenter, designed to evaluate the efficacy and safety of KN026 in combination with chemotherapy.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when CSPC Pharmaceutical Group publishes news
Free account required • Unsubscribe anytime